Drugs / M5542
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06577337 | Sep 2024 → Nov 2026 expected | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M5542 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06577337 ↗ |
| Route | Subcutaneous | “subcutaneously” NCT06577337 ↗ |